Federal Register / Vol. 65, No. 92 / Thursday, May 11, 2000 / Notices 30421

Dated: May 3, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–11761 Filed 5–10–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel;

Oxygen Sensing During Intermittent

Hypoxia.

Date: May 31, 2000.

Time: 8 am to 5 pm.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn Chevy Chase, 5520

Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Anne P Clark, NIH,

NHLBI, DEA, Review Branch, Rockledge II,

6701 Rockledge Drive, Room 7186 Bethesda,

MD 20892–7924, (301) 435–0280.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel;

Mentored Clinical Scientist Development

Awards.

Date: June 15, 2000.

Time: 8 am to 5 pm.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn Bethesda, 8120

Wisconsin Ave, Bethesda, MD 20814.

Contact Person: Eric H Brown, Scientific

Review Administrator, NIH/NHLB/DEA,

Review Branch, Rockledge Building II, 7204,

6701 Rockledge Drive, Bethesda, MD 20892–

7924, (301) 435–0299,

browne@gwgate.nhlbi.nih.gov.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.233, National Center for

Sleep Disorders Research; 93.837, Heart and

Vascular Diseases Research; 93.838, Lung

Diseases Research; 93.839, Blood Diseases

and Resources Research, National Institutes

of Health, HHS)

Dated: May 3, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–11762 Filed 5–10–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse;

Amended Notice Meeting

Notice is hereby given of a change in

the meeting of the National Advisory

Council on Drug Abuse, May 16, 2000,

1 p.m. to May 17, 2000, 11:30 a.m.,

Neuroscience Center, National Institutes

of Health, 6001 Executive Blvd.,

Bethesda, MD 20892 which was

published in the Federal Register on

April 25, 2000, Volume 65 FR 24493.

The agenda of the meeting has been

changed. On May 16, from 1 p.m. to 4

p.m., the meeting will be closed to the

public, and on May 17, from 9 a.m. to

11:30 a.m., the meeting will be open to

the public. The meeting is partially

closed to the public.

Dated: May 4, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–11757 Filed 5–10–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and

Musculoskeletal and Skin Diseases;

Notice of Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

National Arthritis and Musculoskeletal

and Skin Diseases Advisory Council.

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications

and/or contract proposals and the

discussions could disclose confidential

trade secrets or commercial property

such as patentable material, and

personal information concerning

individuals associated with the grant

applications and/or contract proposals,

the disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Arthritis and

Musculoskeletal and Skin Diseases Advisory

Council.

Date: June 12, 2000.

Open: 8:30 am to 12:00 pm.

Agenda: The meeting will be open to the

public to discuss administrative details

relating to Council business and special

reports.

Place: 9000 Rockville Pike, Building 31C,

Conference Room 6, Bethesda, MD 20892.

Closed: 1:00 pm to 5:00 pm.

Agenda: To review and evaluate grant

applications and/or proposals.

Place: 9000 Rockville Pike, Building 31C,

Conference Room 6, Bethesda, MD 20892.

Contact Person: Steven J. Hausman, Deputy

Director, NIAMS/NIH, Bldg 31, Room 4C–32,

31 Center Dr., MSC 2350, Bethesda, MD

20892–2350.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.846, Arthritis,

Musculoskeletal and Skin Diseases Research,

National Institutes of Health, HHS)

Dated: May 4, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–11764 Filed 5–10–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Deafness and

Other Communication Disorders;

Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

properly such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute on

Deafness and Other Communications

Disorders Special Emphasis Panel.